Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corporation - Common Stock
(NQ:
ABUS
)
4.810
+0.190 (+4.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,069,761
Open
4.610
Bid (Size)
4.740 (800)
Ask (Size)
4.840 (500)
Prev. Close
4.620
Today's Range
4.590 - 5.050
52wk Range
2.705 - 5.100
Shares Outstanding
99,161,234
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum
↗
October 21, 2025
Arbutus Biopharma (ABUS) shows strong technical health and high-growth momentum, with surging sales and earnings, positioning it for potential gains.
Via
Chartmill
Performance
YTD
N/A
N/A
1 Month
+14.3%
+14.3%
3 Month
+4.8%
+4.8%
6 Month
+50.8%
+50.8%
1 Year
+47.1%
+47.1%
More News
Read More
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
October 07, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus (ABUS) Q2 Revenue Surges 529%
↗
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
June 25, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 07, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
March 27, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
March 03, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Provides 2025 Corporate and Financial Update
January 13, 2025
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
December 03, 2024
From
Whitefort Capital Management, LP
Via
Business Wire
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
November 26, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
November 20, 2024
Via
Benzinga
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
October 23, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
↗
October 03, 2024
Via
Benzinga
Topics
Intellectual Property
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 01, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
September 03, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Frequently Asked Questions
Is Arbutus Biopharma Corporation - Common Stock publicly traded?
Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
What is the current price of Arbutus Biopharma Corporation - Common Stock?
The current price of Arbutus Biopharma Corporation - Common Stock is 4.810
When was Arbutus Biopharma Corporation - Common Stock last traded?
The last trade of Arbutus Biopharma Corporation - Common Stock was at 12/31/25 04:00 PM ET
What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
The market capitalization of Arbutus Biopharma Corporation - Common Stock is 476.97M
How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
Arbutus Biopharma Corporation - Common Stock has 477M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.